Abstract
In the past Generalized anxiety disorder (GAD)--previously classified as anxiety neurosis--was regarded as not being a separate diagnostic entity. On the basis of new explicit criteria for GAD in the 90ies, GAD-specific pharmacological (i.e. SNRI) and psychological treatments with improved efficacy have become available. The Generalized Anxiety and Depression in Primary care study (GAD-P) investigates the prevalence of GAD in primary care settings and evaluates the patterns of care provided. Aims, methods and findings of the GAD-P study are described in this supplement.
Publication types
-
Comparative Study
-
English Abstract
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Anxiety Agents / therapeutic use
-
Antidepressive Agents, Second-Generation / therapeutic use
-
Anxiety Disorders* / diagnosis
-
Anxiety Disorders* / epidemiology
-
Anxiety Disorders* / therapy
-
Cyclohexanols / therapeutic use
-
Diagnosis, Differential
-
Humans
-
Middle Aged
-
Prevalence
-
Primary Health Care
-
Selective Serotonin Reuptake Inhibitors / therapeutic use
-
Surveys and Questionnaires
-
Venlafaxine Hydrochloride
Substances
-
Anti-Anxiety Agents
-
Antidepressive Agents, Second-Generation
-
Cyclohexanols
-
Serotonin Uptake Inhibitors
-
Venlafaxine Hydrochloride